ERBB2 and neoplasm: In fact, after priming with anti-HER2 treatment, tumours that were HER2-enriched at baseline showed higher densities of all four immune cell subpopulations, highlighting the differential activation of the immune system towards the disease after priming with anti-HER2 treatment according to tumour biology.